Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pemetrexed - Eli Lilly and Company

Next Previous
Drug Profile

Pemetrexed - Eli Lilly and Company

Alternative Names: Alimta; LY-231514; LY-231514 disodium; MTA; Multitargeted antifolate; Pemetrexed disodium

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly; Eli Lilly and Company; John Wayne Cancer Institute; Merck Sharp & Dohme; University of California, Davis; Virginia Commonwealth University
  • Class Antineoplastics; Benzamides; Glutamates; Hypoxanthines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Antimetabolites; Tetrahydrofolate dehydrogenase inhibitors; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Mesothelioma; Non-small cell lung cancer
  • Phase II Breast cancer
  • Phase I/II Solid tumours
  • No development reported Chordoma; Head and neck cancer; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Renal cell carcinoma
  • Discontinued Small cell lung cancer

Most Recent Events

  • 29 Jun 2023 Efficacy and adverse events data from a phase III KEYNOTE-671 trial in Non-small cell lung cancer released by MSD Pharmaceuticals
  • 22 Jun 2023 Merck completes the phase III KEYNOTE-189 trial for Non small cell lung cancer (First line therapy, Combination therapy) in in Ireland, Germany, the UK, Austria, Belgium, Spain, the Netherlands, Finland, Japan and Denmark (NCT02578680) (JapicCTI163421) (EudraCT2015-003694-15)
  • 18 Jan 2023 Eli Lilly and Company and Saint John's Cancer Institute completes a phase-I clinical trial in Chordoma in USA (IV) (NCT03955042)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top